Search results
Results from the WOW.Com Content Network
In Australia, modafinil is considered to be a Schedule 4 prescription-only medicine. This means that it is a drug with a perceived low potential for abuse and low risk of dependence; still, the use of Schedule 4 drugs in Australia is restricted to those who have a valid prescription from a medical practitioner; import from abroad is illegal. [177]
In Australia, and the United States, Armodafinil is considered to be a Schedule 4 prescription-only medicine or prescription animal remedy. [30] Schedule 4 is defined as "Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a ...
A psychedelic substance is a psychoactive drug whose primary action is to alter cognition and perception. Psychedelics tend to affect and explore the mind in ways that result in the experience being qualitatively different from those of ordinary consciousness. The psychedelic experience is often compared to non-ordinary forms of consciousness ...
For premium support please call: 800-290-4726 more ways to reach us
Modafinil and its analogues are known to act as dopamine reuptake inhibitors and this is thought to be involved in their wakefulness-promoting effects. [1] Chemically , fladrafinil is a derivative of adrafinil ( N -hydroxymodafinil) and is also known as bisfluoroadrafinil (it is the bis (4- fluoro ) phenyl ring - substituted derivative of ...
Eugeroics, in the sense of modafinil-type wakefulness promoting agents, include modafinil itself, armodafinil, and adrafinil, among others. [9] They are medically indicated for the treatment of certain sleep disorders , including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).
Modafinil is a drug that helps keep people awake and alert (wakefulness-promoting agent or "eugeroic"). [ 1 ] [ 2 ] Most of the listed modafinil analogues are drugs that specifically target dopamine reuptake (reabsorption of a neurotransmitter by a neurotransmitter transporter ) with stronger effects ( selective DRIs with improved potency ...
Modafinil appeared to be more potent than adrafinil in animal studies, and was selected for further clinical development, with both adrafinil and modafinil eventually reaching the market. [18] Modafinil was first approved in France in 1994, and then in the United States in 1998. [19] Lafon was acquired by Cephalon in 2001. [20]